Drugs

Sarah Sammons: How does Sacituzumab Govitecan perform in active BC brain metastases?

Sarah Sammons/medicine.duke.edu

Apr 8, 2025, 09:45

Sarah Sammons: How does Sacituzumab Govitecan perform in active BC brain metastases?

Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post on X:

“How does SG perform in Active BC brain metastases?

33 patients with HER2-negative MBC and CNS metastases.

CNS ORR = 4/30 (13%)

Median CNS-progression-free survival=2.9 months (95%CI:2.0–4.3)

Huge area of unmet need.”

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

Authors: Thomas Grinda, Sarah Sammons et al.

Sacituzumab Govitecan

Antonio Giordano Ayal A. Aizer cancer Jose P Leone Liangge Hsu Melissa Hughes Nancy U Lin OncoDaily Oncology Ross J. Kusmick Sara M. Tolaney Sarah L Sammons Stefania Morganti Tae-Kyung Yoo Thomas Grinda

Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care

Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025

World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care

16 Posts Not to Miss From WCLC 2025 Part 1

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Science

Sep 7, 2025, 15:52

Paolo Tarantino: ctDNA Analysis of SONIA Has Been Published in Nature Medicine

Insight

Sep 7, 2025, 15:47

Highlights from SOHO 2025 Annual Meeting

Voices

Sep 7, 2025, 15:42

Brunilda Profka Haxhiu: Radiotherapy Must be Seen as a Right, not a Privilege

Voices

Sep 7, 2025, 15:41

Lisa Lacasse: Highlighting the Potential of Multi-Cancer Early Detection Tests

Blog Posts

Sep 7, 2025, 15:37

Ana Barac: New Era of Myocardial Strain at ASE 2025

Voices

Sep 7, 2025, 15:32

Sumanta Pal: Contribution of IO in TKI/IO Combinations For Non-Clear Cell Kidney Cancer

Voices

Sep 7, 2025, 15:24

Katie Coleman: “What Do Patients Want” is a Moving Target

Insight

Sep 7, 2025, 15:17

Udhayvir Grewal: Palliative Care and End-of-Life Care in Esophageal Cancer

Voices

Sep 7, 2025, 14:57

Zeynep Ozay: Learning and Growing at Huntsman Cancer Institute

Insight

Sep 7, 2025, 14:57

Gerry Hanna Spotlights Editorial on Reframing Radiotherapy in Radiation Oncology

Voices

Sep 7, 2025, 14:41

Roberto Borea: My Very First WCLC 2025 as an IASLC Academy Member

Insight

Sep 7, 2025, 14:29

R. Bryan Rumble: ASCO Guideline Clinical Insights - Systemic therapy in mCRPC